Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment

Document Sample
Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment Powered By Docstoc
					                Bone and Joint Infection Market to 2016 - Medical
                  Imaging and PCR Methods to Facilitate Early
                           Diagnosis and Treatment
 Reference Code: GBIHC063MR                                                                                          Publication Date: February 2011

                                      The Bone and Joint Infection Market is Forecast to Growth to 2016
                                      GBI research analysis suggests that the global bone and joint infections therapeutics market was
The global bone and joint             worth $0.7 billion in 2009 and this is forecast to grow at a Compound Annual Growth Rate (CAGR)
infection market contains             of 8.1% over the next seven years to reach $1.2 billion by 2016. The main reasons for this growth
very few branded                      are the rise in the prevalence and diagnosis of bone and joint infections and the increasing use of
molecules for the                     newly launched antibiotics for the treatment of such infections. However, future market revenue is
treatment. Major share of             forecasted to be reduced due to the impact of the patent expiry of Zyvox and Cubicin in 2015 and
bone and joint infection              2016 respectively. Nevertheless, this impact is expected to be softened by the increase in the
therapeutics is distributed           revenue contribution of pipeline products for the treatment of complicated bone and joint infections.
among the generics
market.                                 Bone and Joint Infection Market Revenue and Forecasts ($bn), 2001–2016
                                                            1.4




                                                            1.2



                                                                                                   CAGR (2009-2016): 8.1%
                                                            1.0




                                                            0.8
                                            Revenue ($bn)




                                                                  CAGR (2001-2009): 6.4%

                                                            0.6




                                                            0.4




                                                            0.2




                                                            -
                                                                      2001                           2010                           2016


                                        Source: GBI Research



                                      Competition among Marketed Products is Strong in the Bone and Joint Infection Market
                                      GBI Research has analyzed the current competitive landscape for bone and joint infections
                                      therapeutics drugs and has found the competition to be strong. There are more than 30 types of
                                      antibiotics used to treat bone and joint infections. Almost all the marketed products have strong
                                      efficacy and good safety profiles. In addition, many generic products, such as penicillins, are
                                      available at low cost so therefore there is intense competition in the market. Quinolones, penicillins,
                                      aminoglycosides, carbpenems and many other generics have emerged as the most prescribed
                                      antibiotics for bone and joint infections due to their excellent efficacy and safety profiles. They have
                                      replaced oxacillins, vancomycin, daptomycin,and third and fourth generation cephalosporins as the
                                      first-choice of treatment, despite the latter being recommended as the therapeutic option in the
                                      guidelines of major international institutions. The patent expiry of Zyvox and Cubicin may increase
                                      the competition in the market. Cephalosporins are expected to capture most of the market available
                                      for other generics due to their efficacious advantage.


Bone and Joint Infection Market to 2016 - Medical                                                                      GBIHC063MR /Published FEB 2011
Imaging and PCR Methods to Facilitate Early
Diagnosis and Treatment                                                                                                                           Page 1
                                                                                   © GBI Research. This is a licensed product and is not to be photocopied
                                      Efficacy and Safety Profiles of Off-Patent Marketed Products Decreases Market
                                      Attractiveness for New Entrants
                                      GBI Research has found that the global bone and joint infections therapeutics market is not very
                                      attractive for investors looking to generate significant revenues from the market. The market has
                                      highly efficacious drugs with good safety profiles and therefore the currently marketed products
                                      meet the needs of most of the patient population. In addition, highly prescribed antibiotics such as
                                      quinolones, penicillins, aminoglycosides, cephalosporins, and carbapenems are already available
                                      as low cost generics. The unmet needs in the market are very small for investors to capitalize on.
                                      These unmet needs are due to the increasing bacterial resistance to the current set of antibiotics.
                                      Pharmaceutical companies are therefore focusing on the development of antibiotics for resistant
                                      strains and are most active in this area of clinical development. Molecules that can treat strains
                                      resistant to most of the prescribed therapies are expected to cover the unmet needs of the bone
                                      and joint infections therapeutics market.




Bone and Joint Infection Market to 2016 - Medical                                                           GBIHC063MR /Published FEB 2011
Imaging and PCR Methods to Facilitate Early
Diagnosis and Treatment                                                                                                                 Page 2
                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                      1         Table of Contents
                                      1   Table of Contents ........................................................................................................................ 3
                                          1.1    List of Tables..................................................................................................................... 5
                                          1.2    List of Figures ................................................................................................................... 8
                                      2   Bone and Joint Infecmtion Market to 2016: Introduction............................................................ 10
                                          2.1    GBI Research Report Guidance ..................................................................................... 10
                                      3   Bone and Joint Infection Market to 2016: Market Overview ...................................................... 11
                                          3.1    Introduction ..................................................................................................................... 11
                                          3.2    Revenue Forecasts for the Global Bone and Joint Infection Market ............................... 11
                                             3.2.1    Revenue .................................................................................................................. 11
                                             3.2.2    Annual Cost of Treatment (ACT) ............................................................................. 13
                                             3.2.3    Treatment Usage Patterns ...................................................................................... 14
                                      4   Bone and Joint Infection Market to 2016: Geographical Landscape.......................................... 20
                                          4.1    Revenue Analysis by Geography .................................................................................... 20
                                          4.2    The US ............................................................................................................................ 22
                                             4.2.1    Revenue .................................................................................................................. 22
                                             4.2.2    Annual Cost of Treatment (ACT) ............................................................................. 23
                                             4.2.3    Treatment Usage Patterns ...................................................................................... 24
                                          4.3    Top Five Countries in Europe ......................................................................................... 29
                                             4.3.1    Revenue .................................................................................................................. 29
                                             4.3.2    Annual Cost of Treatment (ACT) ............................................................................. 30
                                             4.3.3    Treatment Usage Patterns ...................................................................................... 31
                                          4.4    Japan .............................................................................................................................. 37
                                             4.4.1    Revenue .................................................................................................................. 37
                                             4.4.2    Annual Cost of Treatment (ACT) ............................................................................. 38
                                             4.4.3    Treatment Usage Patterns ...................................................................................... 39
                                      5   Bone and Joint Infection Market to 2016: Therapeutic Landscape ............................................ 45
                                          5.1    Prosthetic Joint Infections Therapeutics Market.............................................................. 45
                                             5.1.1    Introduction .............................................................................................................. 45
                                             5.1.2    Revenue .................................................................................................................. 46
                                             5.1.3    Annual Cost of Treatment ........................................................................................ 47
                                             5.1.4    Treatment Usage Patterns ...................................................................................... 48
                                             5.1.5    Drivers and Barriers for the Prosthetic Joint Infections Therapeutics Market .......... 54
                                             5.1.6    Drivers for the Prosthetic Joint Infections Therapeutics Market ............................... 54
                                             5.1.7    Barriers for the Prosthetic Joint Infections Therapeutics Market.............................. 55
                                             5.1.8    Opportunity and Unmet Need .................................................................................. 55
                                          5.2    Osteomyelitis Therapeutics Market ................................................................................. 55
                                             5.2.1    Introduction .............................................................................................................. 55
                                             5.2.2    Revenue .................................................................................................................. 56
                                             5.2.3    Annual Cost of Treatment (ACT) ............................................................................. 57
                                             5.2.4    Treatment Usage Patterns ...................................................................................... 58
                                             5.2.5    Drivers and Barriers for the Osteomyelitis Therapeutics Market.............................. 64
                                             5.2.6    Drivers for the Osteomyelitis Therapeutics Market .................................................. 64
                                             5.2.7    Barriers for the Osteomyelitis Therapeutics Market ................................................. 65
                                             5.2.8    Opportunity and Unmet Need .................................................................................. 65
                                          5.3    Septic Arthritis Therapeutics Market ............................................................................... 65
                                             5.3.1    Introduction .............................................................................................................. 65
                                             5.3.2    Revenue .................................................................................................................. 66
                                             5.3.3    Annual Cost of Treatment (ACT) ............................................................................. 67
                                             5.3.4    Treatment Usage Patterns ...................................................................................... 68
                                             5.3.5    Drivers and Barriers for the Septic Arthritis Therapeutics Market ............................ 74
                                             5.3.6    Drivers for the Septic Arthritis Therapeutics Market ................................................ 74
                                             5.3.7    Barriers for the Septic Arthritis Therapeutics market ............................................... 75
                                             5.3.8    Opportunity and Unmet Need .................................................................................. 75


Bone and Joint Infection Market to 2016 - Medical                                                                                       GBIHC063MR /Published FEB 2011
Imaging and PCR Methods to Facilitate Early
Diagnosis and Treatment                                                                                                                                                       Page 3
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                      6 Bone and Joint Infection Market to 2016: Pipeline Analysis ...................................................... 76
                                        6.1    Introduction ..................................................................................................................... 76
                                           6.1.1    Research and Development Pipeline-Bone and Joint Infection ............................... 76
                                        6.2    Profiles of Key Late Stage Drugs in the Bone and Joint Infection Market ....................... 81
                                           6.2.1    Pagibaximab ............................................................................................................ 81
                                           6.2.2    TAKSTA .................................................................................................................. 81
                                           6.2.3    V710 ........................................................................................................................ 82
                                           6.2.4    Ceftobiprole ............................................................................................................. 82
                                           6.2.5    Teflaro ..................................................................................................................... 84
                                           6.2.6    Torezolid .................................................................................................................. 86
                                           6.2.7    Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13 ...................................... 87
                                      7 Bone and Joint Infection Market to 2016: Competitive Landscape ............................................ 89
                                        7.1    Overview ......................................................................................................................... 89
                                        7.2    Competitive Profiling ....................................................................................................... 89
                                           7.2.1    Sandoz GmbH ......................................................................................................... 89
                                           7.2.2    GlaxoSmithKline ...................................................................................................... 91
                                           7.2.3    F. Hoffmann-La Roche Ltd. ..................................................................................... 93
                                           7.2.4    Ranbaxy .................................................................................................................. 94
                                           7.2.5    Bayer AG ................................................................................................................. 96
                                           7.2.6    Teva Pharmaceutical Industries Limited .................................................................. 99
                                           7.2.7    Eli Lilly and Company ............................................................................................ 102
                                           7.2.8    Pfizer Inc. .............................................................................................................. 104
                                           7.2.9    Hospira, Inc. .......................................................................................................... 106
                                           7.2.10 LEO Pharma A/S ................................................................................................... 107
                                           7.2.11 APP Pharmaceuticals, Inc. .................................................................................... 108
                                           7.2.12 Abbott Laboratories ............................................................................................... 109
                                      8 Bone and Joint Infection Market to 2016: M&A Landscape ..................................................... 111
                                        8.1    Global Bone and Joint Infection Market ........................................................................ 111
                                           8.1.1    Overview: Deals by Type ....................................................................................... 111
                                        8.2    Mergers and Acquisitions .............................................................................................. 112
                                           8.2.1    Overview ............................................................................................................... 112
                                           8.2.2    Durata Therapeutics Acquires Vicuron Pharmaceuticals ....................................... 112
                                           8.2.3    Aptuit Acquires Medicines Research Centre from GlaxoSmithKline ...................... 112
                                           8.2.4    Hospira Acquires Pliva .......................................................................................... 113
                                        8.3    Licensing Agreements .................................................................................................. 114
                                           8.3.1    GlaxoSmithKline (GSK) and Isis Pharmaceuticals ................................................ 114
                                           8.3.2    Sanofi-aventis and Novozymes ............................................................................. 114
                                           8.3.3    Deals by Geography .............................................................................................. 114
                                           8.3.4    Deals by Year ........................................................................................................ 115
                                      9 Bone and Joint Infection Market to 2016: Appendix ................................................................ 116
                                        9.1    Market Definition ........................................................................................................... 116
                                        9.2    Abbreviations ................................................................................................................ 116
                                        9.3    Research Methodology ................................................................................................. 117
                                           9.3.1    Coverage ............................................................................................................... 117
                                           9.3.2    Secondary Research ............................................................................................. 117
                                           9.3.3    Forecasting ............................................................................................................ 118
                                           9.3.4    Primary Research .................................................................................................. 120
                                           9.3.5    Expert Panels ........................................................................................................ 120
                                        9.4    Contact Us .................................................................................................................... 120
                                        9.5    Disclaimer ..................................................................................................................... 121
                                        9.6    Sources ......................................................................................................................... 121




Bone and Joint Infection Market to 2016 - Medical                                                                                    GBIHC063MR /Published FEB 2011
Imaging and PCR Methods to Facilitate Early
Diagnosis and Treatment                                                                                                                                                   Page 4
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      1.1     List of Tables
                                      Table 1:      Bone and Joint Infection Market, Global, Revenue ($bn), 2001-2009 ............................ 12
                                      Table 2:      Bone and Joint Infection Market, Global, Revenue Forecasts ($bn), 2009-2016 ........... 12
                                      Table 3:      Bone and Joint Infection Market, Global, Annual Cost of Treatment ($), 2001-2009 .... 13
                                      Table 4:      Bone and Joint Infection Market, Global, Annual Cost of Treatment ($), 2009-20016 ... 13
                                      Table 5:      Bone and Joint Infection Market, Global, Treatment Usage Patterns (thousands), 2001 -
                                                    2009 ............................................................................................................................... 14
                                      Table 6:      Bone and Joint Infection Market, Global, Treatment Usage Patterns (thousands), 2009 -
                                                    2016 ............................................................................................................................... 15
                                      Table 7:      Bone and Joint Infection Market, Global, Diseased Population (thousands) 2001–200916
                                      Table 8:      Bone and Joint Infection Market, Global, Diseased Population (thousands) 2009–2016
                                                    ....................................................................................................................................... 16
                                      Table 9:      Bone and Joint Infection Market, Global, Treatment Seeking Population (thousands)
                                                    2001–2009 ..................................................................................................................... 17
                                      Table 10:     Bone and Joint Infection Market, Global, Treatment Seeking Population (thousands)
                                                    2009–2016 ..................................................................................................................... 17
                                      Table 11:     Bone and Joint Infection Market, Global, Diagnosed Population (thousands), 2001–2009
                                                    ....................................................................................................................................... 18
                                      Table 12:     Bone and Joint Infection Market, Global, Diagnosed Population (thousands) 2009–2016
                                                    ....................................................................................................................................... 18
                                      Table 13:     Bone and Joint Infection Market, Global, Prescription Population (thousands) 2001–2009
                                                    ....................................................................................................................................... 19
                                      Table 14:     Bone and Joint Infection Market, Global, Prescription Population (thousands) 2009–2016
                                                    ....................................................................................................................................... 19
                                      Table 15:     Bone and Joint Infection Market, Global, Revenue Analysis by Geography ($m), 2001-
                                                    2009 ............................................................................................................................... 21
                                      Table 16:     Bone and Joint Infection Market, Global, Revenue Analysis by Geography ($m), 2009-
                                                    2016 ............................................................................................................................... 21
                                      Table 17:     Bone and Joint Infection Market, The US, Revenue ($m), 2001-2009 ........................... 22
                                      Table 18:     Bone and Joint Infection Market, The US, Revenue Forecast ($m), 2009-2016 ............ 22
                                      Table 19:     Bone and Joint Infection Market, The US, Annual Cost of Treatment($), 2001-2009.... 23
                                      Table 20:     Bone and Joint Infection Market, The US, Annual Cost of Treatment($), 2009-2016.... 23
                                      Table 21:     Bone and Joint Infection Market, The US, Treatment Usage Patterns, 2001–2009 ....... 24
                                      Table 22:     Bone and Joint Infection Market, The US, Treatment Usage Patterns, 2009–2016 ....... 24
                                      Table 23:     Bone and Joint Infection Market, The US, Diseased Population (thousands) 2001–2009
                                                    ....................................................................................................................................... 25
                                      Table 24:     Bone and Joint Infection Market, The US, Diseased Population (thousands) 2009–2016
                                                    ....................................................................................................................................... 25
                                      Table 25:     Bone and Joint Infection Market, The US, Treatment Seeking Population (thousands)
                                                    2001–2009 ..................................................................................................................... 26
                                      Table 26:     Bone and Joint Infection Market, The US, Treatment Seeking Population (thousands)
                                                    2009–2016 ..................................................................................................................... 26
                                      Table 27:     Bone and Joint Infection Market, The US, Diagnosed Population (thousands) 2001–2009
                                                    ....................................................................................................................................... 27
                                      Table 28:     Bone and Joint Infection Market, The US, Diagnosed Population (thousands) 2009–2016
                                                    ....................................................................................................................................... 27
                                      Table 29:     Bone and Joint Infection Market, The US, Prescription Population (thousands) 2001–
                                                    2009 ............................................................................................................................... 28
                                      Table 30:     Bone and Joint Infection Market, The US, Prescription Population (thousands) 2009–
                                                    2016 ............................................................................................................................... 28
                                      Table 31:     Bone and Joint Infection Market, Top Five countries in Europe, Revenue ($m), 2001-
                                                    2009 ............................................................................................................................... 29
                                      Table 32:     Bone and Joint Infection Market, Top Five countries in Europe, Revenue Forecasts
                                                    ($m), 2009-2016............................................................................................................. 29
                                      Table 33:     Bone and Joint Infection Market, Top Five Countries in Europe, Annual Cost of
                                                    Treatment ($), 2001-2009 .............................................................................................. 30
                                      Table 34:     Bone and Joint Infection Market, Top Five Countries in Europe, Annual Cost of
                                                    Treatment ($), 2009-2016 .............................................................................................. 30
                                      Table 35:     Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Usage
                                                    Patterns (thousands), 2001-2009 ................................................................................... 31
                                      Table 36:     Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Usage
                                                    Patterns (thousands), 2009-2016 ................................................................................... 32

Bone and Joint Infection Market to 2016 - Medical                                                                                          GBIHC063MR /Published FEB 2011
Imaging and PCR Methods to Facilitate Early
Diagnosis and Treatment                                                                                                                                                            Page 5
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                      Table 37: Bone and Joint Infection Market, Top Five Countries in Europe, Diseased Population
                                                (thousands) 2001–2009 ................................................................................................. 33
                                      Table 38: Bone and Joint Infection Market, Top Five Countries in Europe, Diseased Population
                                                (thousands) 2009–2016 ................................................................................................. 33
                                      Table 39: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Seeking
                                                Population (thousands) 2001–2009 ............................................................................... 34
                                      Table 40: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Seeking
                                                Population (thousands) 2009–2016 ............................................................................... 34
                                      Table 41: Bone and Joint Infection Market, Top Five Countries in Europe, Diagnosed Population
                                                (thousands) 2001–2009 ................................................................................................. 35
                                      Table 42: Bone and Joint Infection Market, Top Five Countries in Europe, Diagnosed Population
                                                (thousands) 2009–2016 ................................................................................................. 35
                                      Table 43: Bone and Joint Infection Market, Top Five Countries in Europe, Prescription Population
                                                (thousands) 2001–2009 ................................................................................................. 36
                                      Table 44: Bone and Joint Infection Market, Top Five Countries in Europe, Prescription Population
                                                (thousands) 2009–2016 ................................................................................................. 36
                                      Table 45: Bone and Joint Infection Market, Japan, Revenue ($m), 2001-2009 ............................. 37
                                      Table 46: Bone and Joint Infection Market, Japan, Revenue ($m), 2009-2016 ............................. 37
                                      Table 47: Bone and Joint Infection Market, Japan, Annual Cost of Treatment ($), 2001-2009 ..... 38
                                      Table 48: Bone and Joint Infection Market, Japan, Annual Cost of Treatment($), 2009-2016 ....... 38
                                      Table 49: Bone and Joint Infection Market, Japan, Treatment Usage Patterns (thousands), 2001-
                                                2009 ............................................................................................................................... 39
                                      Table 50:Bone and Joint Infection Market, Japan, Treatment Usage Patterns (thousands), 2009-
                                                2016 ............................................................................................................................... 40
                                      Table 51: Bone and Joint Infection Market, Japan, Diseased Population (thousands) 2001–2009
                                                ....................................................................................................................................... 41
                                      Table 52: Bone and Joint Infection Market, Japan, Diseased Population (thousands) 2009–2016
                                                ....................................................................................................................................... 41
                                      Table 53: Bone and Joint Infection Market, Japan, Treatment Seeking Population (thousands)
                                                2001–2009 ..................................................................................................................... 42
                                      Table 54: Bone and Joint Infection Market, Japan, Treatment Seeking Population (thousands)
                                                2009–2016 ..................................................................................................................... 42
                                      Table 55: Bone and Joint Infection Market, Japan, Diagnosed Population (thousands) 2001–2009
                                                ....................................................................................................................................... 43
                                      Table 56: Bone and Joint Infection Market, Japan, Diagnosed Population (thousands) 2009–2016
                                                ....................................................................................................................................... 43
                                      Table 57: Bone and Joint Infection Market, Japan, Prescription Population (thousands) 2001–2009
                                                ....................................................................................................................................... 44
                                      Table 58: Bone and Joint Infection Market, Japan, Prescription Population (thousands) 2009–2016
                                                ....................................................................................................................................... 44
                                      Table 59: Prosthetic Joint Infections Therapeutics Market, Global, Revenue ($m), 2001-2009 .... 46
                                      Table 60: Prosthetic Joint Infections Therapeutics Market, Global, Revenue Forecast ($m), 2009-
                                                2016 ............................................................................................................................... 46
                                      Table 61: Prosthetic Joint Infections Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                2001-2009 ...................................................................................................................... 47
                                      Table 62: Prosthetic Joint Infections Therapeutics Market, Global, Annual Cost of Treatment($),
                                                2009-2016 ...................................................................................................................... 47
                                      Table 63: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Usage Patterns
                                                (thousands), 2001-2009 ................................................................................................. 48
                                      Table 64: Prosthetic Joint Infection Therapeutics Market, Global, Treatment Usage Patterns
                                                (thousands), 2009-2016 ................................................................................................. 49
                                      Table 65: Prosthetic Joint Infections Therapeutics Market, Global, Diseased Population
                                                (thousands), 2001-2009 ................................................................................................. 50
                                      Table 66: Prosthetic Joint Infections Therapeutics Market, Global, Diseased Population
                                                (thousands), 2009-2016 ................................................................................................. 50
                                      Table 67: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Seeking Population
                                                (thousands), 2001-2009 ................................................................................................. 51
                                      Table 68: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Seeking Population
                                                (thousands), 2009-2016 ................................................................................................. 51
                                      Table 69: Prosthetic Joint Infections Therapeutics Market, Global, Diagnosed Population
                                                (thousands), 2001-2009 ................................................................................................. 52
                                      Table 70: Prosthetic Joint Infections Therapeutics Market, Global, Diagnosed Population
                                                (thousands), 2009-2016 ................................................................................................. 52

Bone and Joint Infection Market to 2016 - Medical                                                                                        GBIHC063MR /Published FEB 2011
Imaging and PCR Methods to Facilitate Early
Diagnosis and Treatment                                                                                                                                                         Page 6
                                                                                          © GBI Research. This is a licensed product and is not to be photocopied
                                      Table 71: Prosthetic Joint Infections Therapeutics Market, Global, Prescription Population
                                                (thousands), 2001-2009 ................................................................................................. 53
                                      Table 72: Prosthetic Joint Infections Therapeutics Market, Global, Prescription Population
                                                (thousands), 2009-2016 ................................................................................................. 53
                                      Table 73: Osteomyelitis Therapeutics Market, Global, Revenue ($m), 2001-2009 ........................ 56
                                      Table 74: Osteomyelitis Therapeutics Market, Global, Revenue Forecast ($m), 2009-2016 ......... 56
                                      Table 75: Osteomyelitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009
                                                ....................................................................................................................................... 57
                                      Table 76: Osteomyelitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016
                                                ....................................................................................................................................... 57
                                      Table 77: Osteomyelitis Therapeutics Market, Global, Treatment Usage Patterns (thousands),
                                                2001-2009 ...................................................................................................................... 58
                                      Table 78: Osteomyelitis Therapeutics Market, Global, Treatment Usage Patterns (thousands),
                                                2009-2016 ...................................................................................................................... 59
                                      Table 79: Osteomyelitis Therapeutics Market, Global, Diseased Population (thousands), 2001-
                                                2009 ...............................................................
				
DOCUMENT INFO
Description: Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment Summary GBI Research, the leading business intelligence provider, has released its latest research “Bone and Joint Infection Market to 2016- Medical Imaging and PCR methods to Facilitate Early Diagnosis and Treatment”, which provides insights into bone and joint infections market sales and price forecasts until 2016. The report also examines the global bone and joint infections therapies treatment usage patterns. In addition, the geographical distribution of bone and joint infections therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report provides an in-depth analysis of the top three bone and joint infections market therapeutic indications, which are prosthetic joint infection, osteomyelitis and septic arthritis. Furthermore, it also includes the market forecasts and treatment usage patterns of these these therapeutic indications. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving bone and joint infections therapies is also presented. In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts. GBI Research analysis showed that the global bone and joint infections market was estimated at $0.7 billion in 2009, with a year-on-year growth rate of 6.4% between 2001 and 2009. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 8.1% between 2009 and 2016 to record a sales value of $1.2 billion. The patent expiry of two of the branded drugs by 2016 is expected to make way for the entry of generics. Many of the major pharmaceutical companies such as GlaxoSmithKline, Hoffman-La Roche, Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira, Leo pharma A/S, App pharmaceuticals and
BUY THIS DOCUMENT NOW PRICE: $3500 100% MONEY BACK GUARANTEED
PARTNER GBI Research
GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.